drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01143 | DB01197 | 923 | 1,603 | [
"DDInter65",
"DDInter292"
] | Amifostine | Captopril | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
923,
24,
1603
]
],
[
[
923,
63,
610
],
[
610,
1,
1603
]
],
[
[
923,
18,
2801
],
[
2801,
57,
1603
]
],
[
[
923,
21,
28921
],
[
28921,
... | [
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Amifostine (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Captopril (Compound)
Amifostine (Compound) causes Dizziness (Side Effect) and... |
DB00095 | DB12267 | 66 | 1,476 | [
"DDInter623",
"DDInter233"
] | Efalizumab | Brigatinib | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
66,
24,
1476
]
],
[
[
66,
24,
168
],
[
168,
23,
1476
]
],
[
[
66,
24,
629
],
[
629,
24,
1476
]
],
[
[
66,
63,
1184
],
[
1184,
24... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus... |
DB01190 | DB09054 | 568 | 384 | [
"DDInter398",
"DDInter905"
] | Clindamycin | Idelalisib | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
568,
24,
384
]
],
[
[
568,
63,
851
],
[
851,
24,
384
]
],
[
[
568,
24,
859
],
[
859,
24,
384
]
],
[
[
568,
24,
1155
],
[
1155,
6... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Po... |
DB00444 | DB12267 | 63 | 1,476 | [
"DDInter1765",
"DDInter233"
] | Teniposide | Brigatinib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
63,
24,
1476
]
],
[
[
63,
63,
168
],
[
168,
23,
1476
]
],
[
[
63,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
63,
24,
800
],
[
800,
24... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra m... |
DB00635 | DB00754 | 1,573 | 157 | [
"DDInter1515",
"DDInter696"
] | Prednisone | Ethotoin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
1573,
24,
157
]
],
[
[
1573,
24,
759
],
[
759,
40,
157
]
],
[
[
1573,
6,
10215
],
[
10215,
45,
157
]
],
[
[
1573,
7,
7248
],
[
7248,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Prednisone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethotoin (Compound)
Prednisone (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upr... |
DB00586 | DB01039 | 1,512 | 535 | [
"DDInter537",
"DDInter718"
] | Diclofenac | Fenofibrate | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
1512,
24,
535
]
],
[
[
1512,
63,
831
],
[
831,
1,
535
]
],
[
[
1512,
6,
3486
],
[
3486,
45,
535
]
],
[
[
1512,
21,
28936
],
[
28936,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound)
Diclofenac (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fenofibrate (Compound)
Diclofenac (Compound) causes Hyperhidrosis (Side Effect) and... |
DB06822 | DB09030 | 802 | 840 | [
"DDInter1812",
"DDInter1945"
] | Tinzaparin | Vorapaxar | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
802,
25,
840
]
],
[
[
802,
23,
944
],
[
944,
62,
840
]
],
[
[
802,
63,
383
],
[
383,
24,
840
]
],
[
[
802,
64,
885
],
[
885,
24,... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Tinzaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pen... |
DB00400 | DB00474 | 353 | 1,269 | [
"DDInter843",
"DDInter1173"
] | Griseofulvin | Methohexital | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. | Moderate | 1 | [
[
[
353,
24,
1269
]
],
[
[
353,
63,
1023
],
[
1023,
1,
1269
]
],
[
[
353,
24,
536
],
[
536,
40,
1269
]
],
[
[
353,
63,
288
],
[
288,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methohexital"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Methohexital (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Methoh... |
DB00601 | DB06688 | 453 | 1,430 | [
"DDInter1073",
"DDInter1677"
] | Linezolid | Sipuleucel-T | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
453,
24,
1430
]
],
[
[
453,
25,
676
],
[
676,
63,
1430
]
],
[
[
453,
24,
1531
],
[
1531,
24,
1430
]
],
[
[
453,
24,
310
],
[
310,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacit... | Linezolid may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may ... |
DB00281 | DB09036 | 608 | 812 | [
"DDInter1066",
"DDInter1668"
] | Lidocaine | Siltuximab | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
608,
24,
812
]
],
[
[
608,
23,
371
],
[
371,
24,
812
]
],
[
[
608,
24,
523
],
[
523,
24,
812
]
],
[
[
608,
62,
362
],
[
362,
24,... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propafenone"
],
[
... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Propafenone and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazol... |
DB00455 | DB09293 | 1,601 | 116 | [
"DDInter1091",
"DDInter954"
] | Loratadine | Iodide I-131 | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1601,
24,
116
]
],
[
[
1601,
40,
1219
],
[
1219,
24,
116
]
],
[
[
1601,
24,
33
],
[
33,
25,
116
]
],
[
[
1601,
40,
1219
],
[
1219,
... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Loratadine",
"{u} (Compound) resembles {v} (Compound)",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderat... | Loratadine (Compound) resembles Azatadine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening intera... |
DB00023 | DB00860 | 305 | 891 | [
"DDInter127",
"DDInter1513"
] | Asparaginase Escherichia coli | Prednisolone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
305,
24,
891
]
],
[
[
305,
24,
175
],
[
175,
40,
891
]
],
[
[
305,
24,
1561
],
[
1561,
24,
891
]
],
[
[
305,
24,
167
],
[
167,
1... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testos... |
DB00207 | DB09104 | 1,570 | 286 | [
"DDInter157",
"DDInter1118"
] | Azithromycin | Magnesium hydroxide | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1570,
24,
286
]
],
[
[
1570,
24,
820
],
[
820,
23,
286
]
],
[
[
1570,
24,
688
],
[
688,
24,
286
]
],
[
[
1570,
25,
1593
],
[
1593,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Salbutam... |
DB01168 | DB09488 | 1,053 | 103 | [
"DDInter1526",
"DDInter23"
] | Procarbazine | Acrivastine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1053,
24,
103
]
],
[
[
1053,
64,
1405
],
[
1405,
24,
103
]
],
[
[
1053,
63,
146
],
[
146,
24,
103
]
],
[
[
1053,
24,
537
],
[
537,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
],
[
"... | Procarbazine may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Prop... |
DB09312 | DB10315 | 967 | 1,137 | [
"DDInter103",
"DDInter1127"
] | Antilymphocyte immunoglobulin (horse) | Measles virus vaccine live attenuated | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
967,
25,
1137
]
],
[
[
967,
64,
581
],
[
581,
25,
1137
]
],
[
[
967,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
967,
25,
676
],
[
676,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when ... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacer... |
DB00615 | DB11979 | 690 | 1,320 | [
"DDInter1589",
"DDInter625"
] | Rifabutin | Elagolix | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
690,
24,
1320
]
],
[
[
690,
64,
168
],
[
168,
23,
1320
]
],
[
[
690,
62,
608
],
[
608,
23,
1320
]
],
[
[
690,
25,
1297
],
[
1297,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
... | Rifabutin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor in... |
DB00176 | DB04837 | 529 | 649 | [
"DDInter770",
"DDInter407"
] | Fluvoxamine | Clofedanol | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
529,
24,
649
]
],
[
[
529,
24,
1376
],
[
1376,
24,
649
]
],
[
[
529,
24,
832
],
[
832,
40,
649
]
],
[
[
529,
24,
11
],
[
11,
1,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelenn... |
DB04908 | DB12364 | 1,671 | 1,421 | [
"DDInter741",
"DDInter200"
] | Flibanserin | Betrixaban | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1671,
25,
1421
]
],
[
[
1671,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1671,
25,
760
],
[
760,
24,
1421
]
],
[
[
1671,
63,
222
],
[
222,
... | [
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatin... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Flibanserin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may caus... |
DB00282 | DB00515 | 641 | 589 | [
"DDInter1383",
"DDInter387"
] | Pamidronic acid | Cisplatin | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic ... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
641,
24,
589
]
],
[
[
641,
21,
28778
],
[
28778,
60,
589
]
],
[
[
641,
24,
663
],
[
663,
63,
589
]
],
[
[
641,
24,
91
],
[
91,
2... | [
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
... | Pamidronic acid (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cisplatin (Compound)
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate d... |
DB00443 | DB00655 | 251 | 559 | [
"DDInter195",
"DDInter682"
] | Betamethasone | Estrone | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Moderate | 1 | [
[
[
251,
24,
559
]
],
[
[
251,
24,
35
],
[
35,
40,
559
]
],
[
[
251,
40,
1581
],
[
1581,
40,
559
]
],
[
[
251,
63,
380
],
[
380,
40,... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estrone (Compound)
Betamethasone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Estrone (Compound)
Betamethasone may cause a moderate interacti... |
DB00394 | DB04865 | 218 | 4 | [
"DDInter168",
"DDInter1335"
] | Beclomethasone dipropionate | Omacetaxine mepesuccinate | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Bec... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
218,
24,
4
]
],
[
[
218,
7,
3163
],
[
3163,
46,
4
]
],
[
[
218,
18,
6420
],
[
6420,
46,
4
]
],
[
[
218,
6,
1899
],
[
1899,
46,
... | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
... | Beclomethasone dipropionate (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Beclomethasone dipropionate (Compound) downregulates FOSL1 (Gene) and FOSL1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Beclomethasone dipropionate (Compound) bin... |
DB00427 | DB01227 | 1,233 | 1,301 | [
"DDInter1879",
"DDInter1043"
] | Triprolidine | Levacetylmethadol | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1233,
24,
1301
]
],
[
[
1233,
63,
494
],
[
494,
1,
1301
]
],
[
[
1233,
24,
649
],
[
649,
1,
1301
]
],
[
[
1233,
25,
675
],
[
675,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Levacet... |
DB01364 | DB09043 | 22 | 135 | [
"DDInter650",
"DDInter36"
] | Ephedrine | Albiglutide | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
22,
24,
135
]
],
[
[
22,
63,
1252
],
[
1252,
23,
135
]
],
[
[
22,
63,
1052
],
[
1052,
24,
135
]
],
[
[
22,
24,
320
],
[
320,
63,... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may ca... |
DB00792 | DB11915 | 832 | 1,293 | [
"DDInter1878",
"DDInter1909"
] | Tripelennamine | Valbenazine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
832,
24,
1293
]
],
[
[
832,
24,
516
],
[
516,
24,
1293
]
],
[
[
832,
63,
1242
],
[
1242,
24,
1293
]
],
[
[
832,
40,
649
],
[
649,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Ceti... |
DB01181 | DB15066 | 1,532 | 445 | [
"DDInter906",
"DDInter821"
] | Ifosfamide | Givosiran | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
1532,
24,
445
]
],
[
[
1532,
63,
1555
],
[
1555,
24,
445
]
],
[
[
1532,
74,
450
],
[
450,
24,
445
]
],
[
[
1532,
24,
1311
],
[
1311,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Ifosfamide (Compound) resembles Cyclophosphamide (Compound) and Ifosfamide may cause a moderate interaction tha... |
DB00065 | DB00188 | 581 | 168 | [
"DDInter923",
"DDInter222"
] | Infliximab | Bortezomib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Major | 2 | [
[
[
581,
25,
168
]
],
[
[
581,
25,
1307
],
[
1307,
62,
168
]
],
[
[
581,
24,
126
],
[
126,
62,
168
]
],
[
[
581,
24,
1487
],
[
1487,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may... | Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor ... |
DB00280 | DB14723 | 494 | 159 | [
"DDInter575",
"DDInter1026"
] | Disopyramide | Larotrectinib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
494,
24,
159
]
],
[
[
494,
24,
98
],
[
98,
24,
159
]
],
[
[
494,
25,
1181
],
[
1181,
24,
159
]
],
[
[
494,
40,
211
],
[
211,
24,... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Disopyramide may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may c... |
DB00836 | DB11859 | 543 | 418 | [
"DDInter1088",
"DDInter230"
] | Loperamide | Brexanolone | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
543,
24,
418
]
],
[
[
543,
24,
820
],
[
820,
24,
418
]
],
[
[
543,
63,
100
],
[
100,
24,
418
]
],
[
[
543,
40,
649
],
[
649,
24,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine an... |
DB01069 | DB01612 | 401 | 1,637 | [
"DDInter1533",
"DDInter92"
] | Promethazine | Amyl Nitrite | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
401,
24,
1637
]
],
[
[
401,
63,
946
],
[
946,
24,
1637
]
],
[
[
401,
24,
180
],
[
180,
63,
1637
]
],
[
[
401,
24,
993
],
[
993,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and O... |
DB00990 | DB12095 | 1,547 | 179 | [
"DDInter705",
"DDInter1760"
] | Exemestane | Telotristat ethyl | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1547,
24,
179
]
],
[
[
1547,
24,
214
],
[
214,
24,
179
]
],
[
[
1547,
63,
629
],
[
629,
24,
179
]
],
[
[
1547,
1,
891
],
[
891,
... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],... | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus ... |
DB01166 | DB01236 | 477 | 679 | [
"DDInter379",
"DDInter1664"
] | Cilostazol | Sevoflurane | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
477,
24,
679
]
],
[
[
477,
63,
1262
],
[
1262,
40,
679
]
],
[
[
477,
6,
8374
],
[
8374,
45,
679
]
],
[
[
477,
21,
28862
],
[
28862,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Cilostazol (Compound) causes Ventricular tachycardia (Side Effec... |
DB00289 | DB00907 | 847 | 290 | [
"DDInter132",
"DDInter427"
] | Atomoxetine | Cocaine (topical) | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Major | 2 | [
[
[
847,
25,
290
]
],
[
[
847,
6,
2437
],
[
2437,
45,
290
]
],
[
[
847,
21,
28741
],
[
28741,
60,
290
]
],
[
[
847,
24,
1419
],
[
1419,
... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A3"
],
[
"SLC6A3",
"{u} (Gene) is bound by {v} (Compound)",
"Cocaine"... | Atomoxetine may lead to a major life threatening interaction when taken with Cocaine
Atomoxetine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is bound by Cocaine (Compound)
Atomoxetine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Cocaine (Compound)
Atomoxetine may cause a moder... |
DB02701 | DB05528 | 1,632 | 1,070 | [
"DDInter1289",
"DDInter1228"
] | Nicotinamide | Mipomersen | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1632,
25,
1070
]
],
[
[
1632,
24,
384
],
[
384,
64,
1070
]
],
[
[
1632,
63,
1647
],
[
1647,
25,
1070
]
],
[
[
1632,
25,
1510
],
[
1510... | [
[
[
"Nicotinamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelal... | Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Mipomersen
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may lead t... |
DB00041 | DB00242 | 1,648 | 1,064 | [
"DDInter38",
"DDInter392"
] | Aldesleukin | Cladribine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
1648,
25,
1064
]
],
[
[
1648,
24,
372
],
[
372,
64,
1064
]
],
[
[
1648,
24,
1270
],
[
1270,
63,
1064
]
],
[
[
1648,
24,
1245
],
[
1245... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofara... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein deri... |
DB00694 | DB00853 | 51 | 1,686 | [
"DDInter485",
"DDInter1762"
] | Daunorubicin | Temozolomide | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
51,
24,
1686
]
],
[
[
51,
6,
8374
],
[
8374,
45,
1686
]
],
[
[
51,
7,
3349
],
[
3349,
46,
1686
]
],
[
[
51,
18,
8800
],
[
8800,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temozolomide (Compound)
Daunorubicin (Compound) upregulates CAPN1 (Gene) and CAPN1 (Gene) is upregulated by Temozolomide (Compound)
Daunorubicin (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Temozolomide (Compound)
Da... |
DB01263 | DB05773 | 859 | 1,047 | [
"DDInter1494",
"DDInter1848"
] | Posaconazole | Trastuzumab emtansine | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
859,
24,
1047
]
],
[
[
859,
24,
310
],
[
310,
63,
1047
]
],
[
[
859,
64,
467
],
[
467,
24,
1047
]
],
[
[
859,
25,
1593
],
[
1593,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Posaconazole may lead to a major life threatening interaction when taken with Simvastatin and Sim... |
DB00938 | DB06616 | 455 | 594 | [
"DDInter1635",
"DDInter224"
] | Salmeterol | Bosutinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
455,
24,
594
]
],
[
[
455,
6,
8374
],
[
8374,
45,
594
]
],
[
[
455,
7,
1986
],
[
1986,
46,
594
]
],
[
[
455,
18,
1870
],
[
1870,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Salmeterol (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Bosutinib (Compound)
Salmeterol (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Bosutinib (Compound)
Salmeterol (Compoun... |
DB00023 | DB08865 | 305 | 1,593 | [
"DDInter127",
"DDInter448"
] | Asparaginase Escherichia coli | Crizotinib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
305,
24,
1593
]
],
[
[
305,
24,
1247
],
[
1247,
23,
1593
]
],
[
[
305,
24,
1627
],
[
1627,
62,
1593
]
],
[
[
305,
24,
883
],
[
883,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbat... |
DB01234 | DB11967 | 1,220 | 710 | [
"DDInter513",
"DDInter210"
] | Dexamethasone | Binimetinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1220,
24,
710
]
],
[
[
1220,
63,
441
],
[
441,
24,
710
]
],
[
[
1220,
24,
1593
],
[
1593,
24,
710
]
],
[
[
1220,
24,
68
],
[
68,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib a... |
DB00563 | DB01033 | 663 | 328 | [
"DDInter1174",
"DDInter1156"
] | Methotrexate | Mercaptopurine | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Minor | 0 | [
[
[
663,
23,
328
]
],
[
[
663,
5,
11555
],
[
11555,
44,
328
]
],
[
[
663,
6,
5523
],
[
5523,
45,
328
]
],
[
[
663,
21,
28681
],
[
28681,
... | [
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (... | Methotrexate (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mercaptopurine (Compound)
Methotrexate (Compound) binds AOX1 (Gene) and AOX1 (Gene) is bound by Mercaptopurine (Compound)
Methotrexate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Ef... |
DB00295 | DB00404 | 475 | 523 | [
"DDInter1244",
"DDInter54"
] | Morphine | Alprazolam | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Major | 2 | [
[
[
475,
25,
523
]
],
[
[
475,
25,
1418
],
[
1418,
40,
523
]
],
[
[
475,
64,
905
],
[
905,
40,
523
]
],
[
[
475,
25,
1408
],
[
1408,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alprazolam"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Estazolam"
],
[
"Estazolam",
"{u} (Compou... | Morphine may lead to a major life threatening interaction when taken with Estazolam and Estazolam (Compound) resembles Alprazolam (Compound)
Morphine may lead to a major life threatening interaction when taken with Lorazepam and Lorazepam (Compound) resembles Alprazolam (Compound)
Morphine may lead to a major life thre... |
DB00451 | DB06706 | 542 | 468 | [
"DDInter1064",
"DDInter985"
] | Levothyroxine | Isometheptene | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
542,
24,
468
]
],
[
[
542,
24,
633
],
[
633,
24,
468
]
],
[
[
542,
63,
73
],
[
73,
24,
468
]
],
[
[
542,
40,
1152
],
[
1152,
24,... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Lisdexamfetamine and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00247 | DB09098 | 1,131 | 98 | [
"DDInter1194",
"DDInter1700"
] | Methysergide | Somatrem | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1131,
24,
98
]
],
[
[
1131,
24,
159
],
[
159,
63,
98
]
],
[
[
1131,
25,
609
],
[
609,
24,
98
]
],
[
[
1131,
24,
222
],
[
222,
24... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Methysergide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithro... |
DB00615 | DB01229 | 690 | 973 | [
"DDInter1589",
"DDInter1378"
] | Rifabutin | Paclitaxel (protein-bound) | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
690,
24,
973
]
],
[
[
690,
24,
310
],
[
310,
63,
973
]
],
[
[
690,
6,
8374
],
[
8374,
45,
973
]
],
[
[
690,
18,
2183
],
[
2183,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rifabutin ... |
DB00352 | DB00951 | 482 | 1,072 | [
"DDInter1814",
"DDInter986"
] | Tioguanine | Isoniazid | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
482,
24,
1072
]
],
[
[
482,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
482,
24,
1130
],
[
1130,
63,
1072
]
],
[
[
482,
63,
912
],
[
912,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
... |
DB00341 | DB00794 | 1,242 | 759 | [
"DDInter343",
"DDInter1521"
] | Cetirizine | Primidone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
1242,
24,
759
]
],
[
[
1242,
24,
697
],
[
697,
40,
759
]
],
[
[
1242,
63,
362
],
[
362,
1,
759
]
],
[
[
1242,
24,
157
],
[
157,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound... |
DB01068 | DB09036 | 1,565 | 812 | [
"DDInter411",
"DDInter1668"
] | Clonazepam | Siltuximab | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
1565,
24,
812
]
],
[
[
1565,
40,
523
],
[
523,
24,
812
]
],
[
[
1565,
62,
1031
],
[
1031,
24,
812
]
],
[
[
1565,
63,
608
],
[
608,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderat... | Clonazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Clonazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that cou... |
DB00364 | DB01396 | 417 | 1,482 | [
"DDInter1717",
"DDInter553"
] | Sucralfate | Digitoxin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
417,
24,
1482
]
],
[
[
417,
24,
1252
],
[
1252,
1,
1482
]
],
[
[
417,
6,
1829
],
[
1829,
45,
1482
]
],
[
[
417,
24,
286
],
[
286,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Sucralfate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Digitoxin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when ... |
DB00539 | DB11952 | 11 | 800 | [
"DDInter1837",
"DDInter612"
] | Toremifene | Duvelisib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
11,
24,
800
]
],
[
[
11,
24,
1476
],
[
1476,
63,
800
]
],
[
[
11,
24,
522
],
[
522,
24,
800
]
],
[
[
11,
63,
1324
],
[
1324,
24,... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirl... |
DB11110 | DB11915 | 603 | 1,293 | [
"DDInter1115",
"DDInter1909"
] | Magnesium citrate | Valbenazine | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
603,
24,
1293
]
],
[
[
603,
63,
521
],
[
521,
24,
1293
]
],
[
[
603,
24,
927
],
[
927,
24,
1293
]
],
[
[
603,
24,
484
],
[
484,
... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Encorafe... |
DB00059 | DB00563 | 1,560 | 663 | [
"DDInter1404",
"DDInter1174"
] | Pegaspargase | Methotrexate | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1560,
24,
663
]
],
[
[
1560,
24,
328
],
[
328,
62,
663
]
],
[
[
1560,
24,
1154
],
[
1154,
63,
663
]
],
[
[
1560,
24,
109
],
[
109,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pasireoti... |
DB00903 | DB01362 | 1,680 | 497 | [
"DDInter686",
"DDInter960"
] | Etacrynic acid | Iohexol | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
1680,
24,
497
]
],
[
[
1680,
24,
258
],
[
258,
40,
497
]
],
[
[
1680,
21,
28787
],
[
28787,
60,
497
]
],
[
[
1680,
63,
999
],
[
999,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Etacrynic acid (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Etacrynic acid may cause a moderate intera... |
DB00471 | DB08899 | 201 | 129 | [
"DDInter1242",
"DDInter649"
] | Montelukast | Enzalutamide | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
201,
24,
129
]
],
[
[
201,
6,
8374
],
[
8374,
45,
129
]
],
[
[
201,
21,
28703
],
[
28703,
60,
129
]
],
[
[
201,
24,
1247
],
[
1247,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Montelukast (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazo... |
DB00270 | DB00902 | 1,428 | 104 | [
"DDInter993",
"DDInter1168"
] | Isradipine | Methdilazine | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1428,
24,
104
]
],
[
[
1428,
24,
820
],
[
820,
1,
104
]
],
[
[
1428,
24,
401
],
[
401,
63,
104
]
],
[
[
1428,
1,
1081
],
[
1081,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction th... |
DB04868 | DB05679 | 478 | 1,683 | [
"DDInter1293",
"DDInter1907"
] | Nilotinib | Ustekinumab | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
478,
24,
1683
]
],
[
[
478,
64,
1401
],
[
1401,
24,
1683
]
],
[
[
478,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
478,
63,
305
],
[
305,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
],
[
"Procainam... | Nilotinib may lead to a major life threatening interaction when taken with Procainamide and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a... |
DB00106 | DB00697 | 618 | 876 | [
"DDInter4",
"DDInter1821"
] | Abarelix | Tizanidine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
618,
24,
876
]
],
[
[
618,
23,
112
],
[
112,
62,
876
]
],
[
[
618,
24,
401
],
[
401,
63,
876
]
],
[
[
618,
24,
1424
],
[
1424,
2... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promet... |
DB01177 | DB04868 | 77 | 478 | [
"DDInter904",
"DDInter1293"
] | Idarubicin | Nilotinib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
77,
25,
478
]
],
[
[
77,
24,
1468
],
[
1468,
63,
478
]
],
[
[
77,
5,
11555
],
[
11555,
44,
478
]
],
[
[
77,
6,
6017
],
[
6017,
4... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Idarubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib ... |
DB00877 | DB12015 | 629 | 1,033 | [
"DDInter1678",
"DDInter53"
] | Sirolimus | Alpelisib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
629,
24,
1033
]
],
[
[
629,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
629,
63,
576
],
[
576,
24,
1033
]
],
[
[
629,
25,
1510
],
[
1510,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Methadone ... |
DB00673 | DB01105 | 723 | 222 | [
"DDInter112",
"DDInter1665"
] | Aprepitant | Sibutramine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Minor | 0 | [
[
[
723,
23,
222
]
],
[
[
723,
6,
8374
],
[
8374,
45,
222
]
],
[
[
723,
21,
29356
],
[
29356,
60,
222
]
],
[
[
723,
63,
839
],
[
839,
... | [
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Aprepitant (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when ... |
DB01211 | DB08870 | 609 | 850 | [
"DDInter393",
"DDInter228"
] | Clarithromycin | Brentuximab vedotin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
609,
24,
850
]
],
[
[
609,
63,
1570
],
[
1570,
24,
850
]
],
[
[
609,
24,
859
],
[
859,
24,
850
]
],
[
[
609,
25,
1671
],
[
1671,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromyc... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00321 | DB00372 | 21 | 999 | [
"DDInter78",
"DDInter1793"
] | Amitriptyline | Thiethylperazine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
21,
24,
999
]
],
[
[
21,
24,
1614
],
[
1614,
63,
999
]
],
[
[
21,
63,
352
],
[
352,
24,
999
]
],
[
[
21,
40,
1164
],
[
1164,
63,... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and ... |
DB00889 | DB01069 | 1,133 | 401 | [
"DDInter840",
"DDInter1533"
] | Granisetron | Promethazine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1133,
24,
401
]
],
[
[
1133,
25,
1264
],
[
1264,
63,
401
]
],
[
[
1133,
24,
820
],
[
820,
63,
401
]
],
[
[
1133,
63,
1335
],
[
1335,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",... | Granisetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause ... |
DB00069 | DB00175 | 367 | 681 | [
"DDInter946",
"DDInter1509"
] | Interferon alfacon-1 | Pravastatin | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | Moderate | 1 | [
[
[
367,
24,
681
]
],
[
[
367,
24,
1463
],
[
1463,
40,
681
]
],
[
[
367,
24,
126
],
[
126,
62,
681
]
],
[
[
367,
24,
770
],
[
770,
6... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pravastatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovast... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin (Compound) resembles Pravastatin (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interact... |
DB01232 | DB08881 | 1,327 | 868 | [
"DDInter1640",
"DDInter1925"
] | Saquinavir | Vemurafenib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1327,
25,
868
]
],
[
[
1327,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1327,
7,
7972
],
[
7972,
46,
868
]
],
[
[
1327,
18,
3684
],
[
3684,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Saquinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Saquinavir (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Saquinavir (Compound) downregulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Vemurafenib (Compound)
Saquina... |
DB00780 | DB01075 | 551 | 1,376 | [
"DDInter1440",
"DDInter569"
] | Phenelzine | Diphenhydramine | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
551,
24,
1376
]
],
[
[
551,
24,
649
],
[
649,
63,
1376
]
],
[
[
551,
63,
128
],
[
128,
24,
1376
]
],
[
[
551,
24,
832
],
[
832,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenirami... |
DB00969 | DB11791 | 2 | 785 | [
"DDInter52",
"DDInter287"
] | Alosetron | Capmatinib | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
2,
24,
785
]
],
[
[
2,
24,
868
],
[
868,
24,
785
]
],
[
[
2,
63,
1684
],
[
1684,
24,
785
]
],
[
[
2,
24,
1619
],
[
1619,
63,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine... |
DB08816 | DB11791 | 578 | 785 | [
"DDInter1802",
"DDInter287"
] | Ticagrelor | Capmatinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
578,
24,
785
]
],
[
[
578,
23,
1135
],
[
1135,
23,
785
]
],
[
[
578,
63,
1324
],
[
1324,
24,
785
]
],
[
[
578,
24,
868
],
[
868,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazo... |
DB00374 | DB11071 | 1,061 | 1,004 | [
"DDInter1852",
"DDInter1449"
] | Treprostinil | Phenyl salicylate | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
1061,
24,
1004
]
],
[
[
1061,
25,
500
],
[
500,
24,
1004
]
],
[
[
1061,
24,
235
],
[
235,
63,
1004
]
],
[
[
1061,
64,
834
],
[
834,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
... | Treprostinil may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin m... |
DB00637 | DB01238 | 1,557 | 673 | [
"DDInter128",
"DDInter118"
] | Astemizole | Aripiprazole | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1557,
24,
673
]
],
[
[
1557,
25,
851
],
[
851,
1,
673
]
],
[
[
1557,
24,
827
],
[
827,
40,
673
]
],
[
[
1557,
24,
1630
],
[
1630,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodo... | Astemizole may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Astemizole ma... |
DB10315 | DB12001 | 1,137 | 564 | [
"DDInter1127",
"DDInter7"
] | Measles virus vaccine live attenuated | Abemaciclib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
1137,
25,
564
]
],
[
[
1137,
64,
58
],
[
58,
24,
564
]
],
[
[
1137,
25,
351
],
[
351,
24,
564
]
],
[
[
1137,
25,
1476
],
[
1476,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Al... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken wit... |
DB00836 | DB00964 | 543 | 1,617 | [
"DDInter1088",
"DDInter110"
] | Loperamide | Apraclonidine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
543,
24,
1617
]
],
[
[
543,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
543,
63,
876
],
[
876,
40,
1617
]
],
[
[
543,
21,
28666
],
[
28666,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
],
[... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apraclonidine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine (Compound) resembles Apraclonidine (Comp... |
DB00731 | DB00903 | 1,144 | 1,680 | [
"DDInter1269",
"DDInter686"
] | Nateglinide | Etacrynic acid | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
1144,
24,
1680
]
],
[
[
1144,
6,
10612
],
[
10612,
45,
1680
]
],
[
[
1144,
21,
29222
],
[
29222,
60,
1680
]
],
[
[
1144,
24,
1479
],
[
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Com... | Nateglinide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Etacrynic acid (Compound)
Nateglinide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Etacrynic acid (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01192 | DB01246 | 560 | 820 | [
"DDInter1372",
"DDInter45"
] | Oxymorphone | Alimemazine | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
560,
24,
820
]
],
[
[
560,
63,
104
],
[
104,
40,
820
]
],
[
[
560,
63,
401
],
[
401,
24,
820
]
],
[
[
560,
24,
649
],
[
649,
1,
... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction... |
DB12010 | DB15091 | 214 | 676 | [
"DDInter785",
"DDInter1901"
] | Fostamatinib | Upadacitinib | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
214,
24,
676
]
],
[
[
214,
63,
1249
],
[
1249,
24,
676
]
],
[
[
214,
24,
1375
],
[
1375,
24,
676
]
],
[
[
214,
24,
1654
],
[
1654,
... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lef... |
DB04868 | DB09291 | 478 | 741 | [
"DDInter1293",
"DDInter1615"
] | Nilotinib | Rolapitant | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
478,
24,
741
]
],
[
[
478,
63,
211
],
[
211,
23,
741
]
],
[
[
478,
23,
1135
],
[
1135,
23,
741
]
],
[
[
478,
62,
479
],
[
479,
2... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol m... |
DB00366 | DB01224 | 1,594 | 623 | [
"DDInter600",
"DDInter1553"
] | Doxylamine | Quetiapine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1594,
24,
623
]
],
[
[
1594,
24,
827
],
[
827,
1,
623
]
],
[
[
1594,
63,
695
],
[
695,
1,
623
]
],
[
[
1594,
6,
7992
],
[
7992,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Doxy... |
DB00402 | DB01234 | 1,407 | 1,220 | [
"DDInter685",
"DDInter513"
] | Eszopiclone | Dexamethasone | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1407,
24,
1220
]
],
[
[
1407,
10,
11594
],
[
11594,
44,
1220
]
],
[
[
1407,
6,
6017
],
[
6017,
45,
1220
]
],
[
[
1407,
18,
8109
],
[
8... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Eszopiclone",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u}... | Eszopiclone (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Dexamethasone (Compound)
Eszopiclone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexamethasone (Compound)
Eszopiclone (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Dexam... |
DB09104 | DB14568 | 286 | 982 | [
"DDInter1118",
"DDInter1000"
] | Magnesium hydroxide | Ivosidenib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
286,
24,
982
]
],
[
[
286,
64,
1459
],
[
1459,
23,
982
]
],
[
[
286,
62,
700
],
[
700,
24,
982
]
],
[
[
286,
63,
28
],
[
28,
24,... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
],
... | Magnesium hydroxide may lead to a major life threatening interaction when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Atorvastatin and A... |
DB00031 | DB00939 | 20 | 1,338 | [
"DDInter1764",
"DDInter1135"
] | Tenecteplase | Meclofenamic acid | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
20,
24,
1338
]
],
[
[
20,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
20,
24,
1347
],
[
1347,
24,
1338
]
],
[
[
20,
25,
1226
],
[
1226,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Tenecteplase may cause a moderate interaction that could exacerbate diseases when t... |
DB00909 | DB12500 | 306 | 283 | [
"DDInter1971",
"DDInter714"
] | Zonisamide | Fedratinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
306,
24,
283
]
],
[
[
306,
24,
351
],
[
351,
23,
283
]
],
[
[
306,
63,
1419
],
[
1419,
24,
283
]
],
[
[
306,
25,
401
],
[
401,
2... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib m... |
DB04896 | DB08870 | 901 | 850 | [
"DDInter1220",
"DDInter228"
] | Milnacipran | Brentuximab vedotin | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
901,
24,
850
]
],
[
[
901,
63,
267
],
[
267,
24,
850
]
],
[
[
901,
24,
1468
],
[
1468,
63,
850
]
],
[
[
901,
24,
1047
],
[
1047,
... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib ... |
DB00950 | DB11581 | 1,413 | 1,456 | [
"DDInter732",
"DDInter1926"
] | Fexofenadine | Venetoclax | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1413,
24,
1456
]
],
[
[
1413,
24,
241
],
[
241,
63,
1456
]
],
[
[
1413,
23,
86
],
[
86,
24,
1456
]
],
[
[
1413,
24,
165
],
[
165,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Miconazole and Mi... |
DB06237 | DB12010 | 438 | 214 | [
"DDInter141",
"DDInter785"
] | Avanafil | Fostamatinib | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
438,
24,
214
]
],
[
[
438,
64,
723
],
[
723,
24,
214
]
],
[
[
438,
63,
1324
],
[
1324,
24,
214
]
],
[
[
438,
24,
1017
],
[
1017,
... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",... | Avanafil may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may caus... |
DB00781 | DB14115 | 1,481 | 1,312 | [
"DDInter1489",
"DDInter868"
] | Polymyxin B | Human botulinum neurotoxin A/B immune globulin | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle t... | Major | 2 | [
[
[
1481,
25,
1312
]
],
[
[
1481,
24,
123
],
[
123,
24,
1312
]
],
[
[
1481,
25,
1132
],
[
1132,
25,
1312
]
],
[
[
1481,
24,
712
],
[
712,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exen... | Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Polymyxin B may lead to a major life threatening interaction when taken with ... |
DB00624 | DB00877 | 1,561 | 629 | [
"DDInter1775",
"DDInter1678"
] | Testosterone | Sirolimus | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1561,
24,
629
]
],
[
[
1561,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1561,
7,
8224
],
[
8224,
46,
629
]
],
[
[
1561,
18,
12821
],
[
12821,... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Testosterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Testosterone (Compound) upregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Sirolimus (Compound)
Testosterone (Compound) downregulates TRIB1 (Gene) and TRIB1 (Gene) is upregulated by Sirolimus (Compound)
Testosterone (C... |
DB00008 | DB00916 | 491 | 112 | [
"DDInter1407",
"DDInter1202"
] | Peginterferon alfa-2a | Metronidazole | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
491,
24,
112
]
],
[
[
491,
24,
458
],
[
458,
40,
112
]
],
[
[
491,
24,
996
],
[
996,
62,
112
]
],
[
[
491,
24,
322
],
[
322,
23,... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ti... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a mino... |
DB00635 | DB12500 | 1,573 | 283 | [
"DDInter1515",
"DDInter714"
] | Prednisone | Fedratinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1573,
24,
283
]
],
[
[
1573,
24,
351
],
[
351,
23,
283
]
],
[
[
1573,
24,
1339
],
[
1339,
62,
283
]
],
[
[
1573,
63,
1419
],
[
1419,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotr... |
DB12332 | DB14443 | 1,619 | 987 | [
"DDInter1626",
"DDInter1931"
] | Rucaparib | Vibrio cholerae CVD 103-HgR strain live antigen | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1619,
24,
987
]
],
[
[
1619,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1619,
64,
351
],
[
351,
24,
987
]
],
[
[
1619,
25,
676
],
[
676,
... | [
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Rucaparib may lead to a major life threatening interaction when taken with Rib... |
DB04575 | DB09043 | 35 | 135 | [
"DDInter1555",
"DDInter36"
] | Quinestrol | Albiglutide | The 3-cyclopentyl ether of ethinyl estradiol. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
35,
24,
135
]
],
[
[
35,
63,
126
],
[
126,
23,
135
]
],
[
[
35,
63,
870
],
[
870,
24,
135
]
],
[
[
35,
24,
1476
],
[
1476,
63,
... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludro... |
DB00748 | DB10429 | 662 | 200 | [
"DDInter297",
"DDInter282"
] | Carbinoxamine | Candida albicans | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
662,
24,
200
]
],
[
[
662,
63,
701
],
[
701,
24,
200
]
],
[
[
662,
24,
103
],
[
103,
24,
200
]
],
[
[
662,
35,
1376
],
[
1376,
2... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Acrivasti... |
DB00342 | DB00502 | 1,181 | 1,300 | [
"DDInter1770",
"DDInter853"
] | Terfenadine | Haloperidol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Major | 2 | [
[
[
1181,
25,
1300
]
],
[
[
1181,
25,
78
],
[
78,
1,
1300
]
],
[
[
1181,
24,
543
],
[
543,
63,
1300
]
],
[
[
1181,
23,
112
],
[
112,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u... | Terfenadine may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Haloperidol (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate ... |
DB06643 | DB11569 | 1,136 | 1,093 | [
"DDInter500",
"DDInter1003"
] | Denosumab | Ixekizumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1136,
24,
1093
]
],
[
[
1136,
63,
66
],
[
66,
24,
1093
]
],
[
[
1136,
24,
270
],
[
270,
63,
1093
]
],
[
[
1136,
24,
713
],
[
713,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocreliz... |
DB00831 | DB01181 | 1,178 | 1,532 | [
"DDInter1866",
"DDInter906"
] | Trifluoperazine | Ifosfamide | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1178,
24,
1532
]
],
[
[
1178,
7,
8953
],
[
8953,
46,
1532
]
],
[
[
1178,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
1178,
63,
1648
],
[
1... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) upregulates {v} (Gene)",
"NNT"
],
[
"NNT",
"{u} (Gene) is upregulated by ... | Trifluoperazine (Compound) upregulates NNT (Gene) and NNT (Gene) is upregulated by Ifosfamide (Compound)
Trifluoperazine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00295 | DB00683 | 475 | 1,382 | [
"DDInter1244",
"DDInter1212"
] | Morphine | Midazolam | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
475,
24,
1382
]
],
[
[
475,
25,
1216
],
[
1216,
40,
1382
]
],
[
[
475,
64,
905
],
[
905,
40,
1382
]
],
[
[
475,
6,
8374
],
[
8374,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
... | Morphine may lead to a major life threatening interaction when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Morphine may lead to a major life threatening interaction when taken with Lorazepam and Lorazepam (Compound) resembles Midazolam (Compound)
Morphine (Compound) binds CYP3A4 (Gene... |
DB00562 | DB11921 | 1,014 | 1,019 | [
"DDInter188",
"DDInter492"
] | Benzthiazide | Deflazacort | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1014,
24,
1019
]
],
[
[
1014,
24,
959
],
[
959,
24,
1019
]
],
[
[
1014,
1,
359
],
[
359,
24,
1019
]
],
[
[
1014,
24,
1385
],
[
1385,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Benzthiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction... |
DB00285 | DB06764 | 1,100 | 1,090 | [
"DDInter1927",
"DDInter1787"
] | Venlafaxine | Tetryzoline (nasal) | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1100,
24,
1090
]
],
[
[
1100,
24,
144
],
[
144,
63,
1090
]
],
[
[
1100,
24,
688
],
[
688,
24,
1090
]
],
[
[
1100,
1,
643
],
[
643,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Venlaf... |
DB00023 | DB00731 | 305 | 1,144 | [
"DDInter127",
"DDInter1269"
] | Asparaginase Escherichia coli | Nateglinide | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
305,
24,
1144
]
],
[
[
305,
24,
610
],
[
610,
24,
1144
]
],
[
[
305,
24,
50
],
[
50,
63,
1144
]
],
[
[
305,
25,
1510
],
[
1510,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases ... |
DB00619 | DB15093 | 1,419 | 1,654 | [
"DDInter909",
"DDInter1698"
] | Imatinib | Somapacitan | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1419,
24,
1654
]
],
[
[
1419,
63,
608
],
[
608,
23,
1654
]
],
[
[
1419,
63,
10
],
[
10,
24,
1654
]
],
[
[
1419,
25,
1135
],
[
1135,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may caus... |
DB00408 | DB00662 | 1,408 | 717 | [
"DDInter1099",
"DDInter1873"
] | Loxapine | Trimethobenzamide | An antipsychotic agent used in schizophrenia. [PubChem] | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1408,
24,
717
]
],
[
[
1408,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1408,
1,
695
],
[
695,
24,
717
]
],
[
[
1408,
63,
1594
],
[
1594,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Loxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cau... | Loxapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Loxapine may cause a moderate interact... |
DB00835 | DB01142 | 100 | 1,264 | [
"DDInter245",
"DDInter593"
] | Brompheniramine | Doxepin | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
100,
24,
1264
]
],
[
[
100,
63,
508
],
[
508,
24,
1264
]
],
[
[
100,
24,
401
],
[
401,
24,
1264
]
],
[
[
100,
1,
11439
],
[
11439,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.